SCHEMBL3965741

SCHEMBL3965741

CC(C)(C)OC(=O)N1CCCC(CCCN)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
BACE1 P56817 2/20 0.49
CTSD P07339 1/20 0.49
GLS O94925 2/20 0.48
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
SCN9A Q15858 1/20 0.45
ACKR3 P25106 1/20 0.44
FPR3 P25089 1/20 0.43
FPR2 P25090 1/20 0.43
GPR119 Q8TDV5 3/20 0.43
NR1H2 P55055 1/20 0.43
FEN1 P39748 2/20 0.42
KDM1A O60341 1/20 0.42
ALOX5AP P20292 1/20 0.41
FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31511585 0.96 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31511510 0.95 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31420787 0.92 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31421294 0.92 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL30924500 0.92 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31420749 0.92 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL309109 0.92 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL31747257 0.88 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL20310041 0.88 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2ABACE1
SCHEMBL5281960 0.88 GPR119 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed
EP-1989200-A2 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELI LILLY AND COMPANY (US) 2008-11-12 EP disclosed
WO-2007092095-A2 [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. ELI LILLY AND COMPANY (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG MEN1 3407/4885ALDH1A1 2074/4885MAPT 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.